OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Søren Lund Kristensen, Rasmus Rørth, Pardeep S. Jhund, et al.
The Lancet Diabetes & Endocrinology (2019) Vol. 7, Iss. 10, pp. 776-785
Open Access | Times Cited: 1283
Søren Lund Kristensen, Rasmus Rørth, Pardeep S. Jhund, et al.
The Lancet Diabetes & Endocrinology (2019) Vol. 7, Iss. 10, pp. 776-785
Open Access | Times Cited: 1283
Showing 1-25 of 1283 citing articles:
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Theresa A. McDonagh, Marco Metra, Marianna Adamo, et al.
European Heart Journal (2021) Vol. 42, Iss. 36, pp. 3599-3726
Open Access | Times Cited: 8685
Theresa A. McDonagh, Marco Metra, Marianna Adamo, et al.
European Heart Journal (2021) Vol. 42, Iss. 36, pp. 3599-3726
Open Access | Times Cited: 8685
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Frank L.J. Visseren, François Mach, Yvo M. Smulders, et al.
European Heart Journal (2021) Vol. 42, Iss. 34, pp. 3227-3337
Open Access | Times Cited: 4264
Frank L.J. Visseren, François Mach, Yvo M. Smulders, et al.
European Heart Journal (2021) Vol. 42, Iss. 34, pp. 3227-3337
Open Access | Times Cited: 4264
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, David A. D’Alessio, Judith Fradkin, et al.
Diabetes Care (2018) Vol. 41, Iss. 12, pp. 2669-2701
Open Access | Times Cited: 3144
Melanie J. Davies, David A. D’Alessio, Judith Fradkin, et al.
Diabetes Care (2018) Vol. 41, Iss. 12, pp. 2669-2701
Open Access | Times Cited: 3144
2023 ESC Guidelines for the management of acute coronary syndromes
Robert A. Byrne, Xavier Rosselló, J J Coughlan, et al.
European Heart Journal (2023) Vol. 44, Iss. 38, pp. 3720-3826
Open Access | Times Cited: 1848
Robert A. Byrne, Xavier Rosselló, J J Coughlan, et al.
European Heart Journal (2023) Vol. 44, Iss. 38, pp. 3720-3826
Open Access | Times Cited: 1848
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Theresa McDonagh, Marco Metra, Marianna Adamo, et al.
European Journal of Heart Failure (2022) Vol. 24, Iss. 1, pp. 4-131
Open Access | Times Cited: 1508
Theresa McDonagh, Marco Metra, Marianna Adamo, et al.
European Journal of Heart Failure (2022) Vol. 24, Iss. 1, pp. 4-131
Open Access | Times Cited: 1508
Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, David A. D’Alessio, Judith Fradkin, et al.
Diabetologia (2018) Vol. 61, Iss. 12, pp. 2461-2498
Open Access | Times Cited: 1344
Melanie J. Davies, David A. D’Alessio, Judith Fradkin, et al.
Diabetologia (2018) Vol. 61, Iss. 12, pp. 2461-2498
Open Access | Times Cited: 1344
2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
John B. Buse, Deborah J. Wexler, Απόστολος Τσάπας, et al.
Diabetes Care (2019) Vol. 43, Iss. 2, pp. 487-493
Open Access | Times Cited: 1050
John B. Buse, Deborah J. Wexler, Απόστολος Τσάπας, et al.
Diabetes Care (2019) Vol. 43, Iss. 2, pp. 487-493
Open Access | Times Cited: 1050
GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
Michael A. Nauck, Daniel R. Quast, Jakob Wefers, et al.
Molecular Metabolism (2020) Vol. 46, pp. 101102-101102
Open Access | Times Cited: 962
Michael A. Nauck, Daniel R. Quast, Jakob Wefers, et al.
Molecular Metabolism (2020) Vol. 46, pp. 101102-101102
Open Access | Times Cited: 962
KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Ian H. de Boer, Maria Luiza Caramori, Juliana C.N. Chan, et al.
Kidney International (2020) Vol. 98, Iss. 4, pp. S1-S115
Open Access | Times Cited: 962
Ian H. de Boer, Maria Luiza Caramori, Juliana C.N. Chan, et al.
Kidney International (2020) Vol. 98, Iss. 4, pp. S1-S115
Open Access | Times Cited: 962
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
Naveed Sattar, Matthew M.Y. Lee, Søren Lund Kristensen, et al.
The Lancet Diabetes & Endocrinology (2021) Vol. 9, Iss. 10, pp. 653-662
Open Access | Times Cited: 934
Naveed Sattar, Matthew M.Y. Lee, Søren Lund Kristensen, et al.
The Lancet Diabetes & Endocrinology (2021) Vol. 9, Iss. 10, pp. 653-662
Open Access | Times Cited: 934
Chronic kidney disease
Kamyar Kalantar‐Zadeh, Tazeen H. Jafar, Dorothea Nitsch, et al.
The Lancet (2021) Vol. 398, Iss. 10302, pp. 786-802
Open Access | Times Cited: 874
Kamyar Kalantar‐Zadeh, Tazeen H. Jafar, Dorothea Nitsch, et al.
The Lancet (2021) Vol. 398, Iss. 10302, pp. 786-802
Open Access | Times Cited: 874
NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications
Giovanni Targher, Christopher D. Byrne, Herbert Tilg
Gut (2020) Vol. 69, Iss. 9, pp. 1691-1705
Open Access | Times Cited: 575
Giovanni Targher, Christopher D. Byrne, Herbert Tilg
Gut (2020) Vol. 69, Iss. 9, pp. 1691-1705
Open Access | Times Cited: 575
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines
Salim S. Virani, L. Kristin Newby, Suzanne V. Arnold, et al.
Circulation (2023) Vol. 148, Iss. 9
Open Access | Times Cited: 557
Salim S. Virani, L. Kristin Newby, Suzanne V. Arnold, et al.
Circulation (2023) Vol. 148, Iss. 9
Open Access | Times Cited: 557
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
Hertzel C. Gerstein, Naveed Sattar, Julio Rosenstock, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 10, pp. 896-907
Open Access | Times Cited: 521
Hertzel C. Gerstein, Naveed Sattar, Julio Rosenstock, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 10, pp. 896-907
Open Access | Times Cited: 521
2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
John B. Buse, Deborah J. Wexler, Απόστολος Τσάπας, et al.
Diabetologia (2019) Vol. 63, Iss. 2, pp. 221-228
Open Access | Times Cited: 462
John B. Buse, Deborah J. Wexler, Απόστολος Τσάπας, et al.
Diabetologia (2019) Vol. 63, Iss. 2, pp. 221-228
Open Access | Times Cited: 462
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
Bertram Pitt, Jingmei Li, Rajiv Agarwal, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 24, pp. 2252-2263
Open Access | Times Cited: 446
Bertram Pitt, Jingmei Li, Rajiv Agarwal, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 24, pp. 2252-2263
Open Access | Times Cited: 446
2024 ESC Guidelines for the management of chronic coronary syndromes
Christiaan Vrints, Felicita Andreotti, Konstantinos C. Koskinas, et al.
European Heart Journal (2024) Vol. 45, Iss. 36, pp. 3415-3537
Open Access | Times Cited: 440
Christiaan Vrints, Felicita Andreotti, Konstantinos C. Koskinas, et al.
European Heart Journal (2024) Vol. 45, Iss. 36, pp. 3415-3537
Open Access | Times Cited: 440
Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors
Thomas A. Zelniker, Eugene Braunwald
Journal of the American College of Cardiology (2020) Vol. 75, Iss. 4, pp. 422-434
Closed Access | Times Cited: 416
Thomas A. Zelniker, Eugene Braunwald
Journal of the American College of Cardiology (2020) Vol. 75, Iss. 4, pp. 422-434
Closed Access | Times Cited: 416
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Emily Brown, Hiddo J.L. Heerspink, Daniel J. Cuthbertson, et al.
The Lancet (2021) Vol. 398, Iss. 10296, pp. 262-276
Open Access | Times Cited: 383
Emily Brown, Hiddo J.L. Heerspink, Daniel J. Cuthbertson, et al.
The Lancet (2021) Vol. 398, Iss. 10296, pp. 262-276
Open Access | Times Cited: 383
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Frank L.J. Visseren, François Mach, Yvo M. Smulders, et al.
European Journal of Preventive Cardiology (2021) Vol. 29, Iss. 1, pp. 5-115
Open Access | Times Cited: 376
Frank L.J. Visseren, François Mach, Yvo M. Smulders, et al.
European Journal of Preventive Cardiology (2021) Vol. 29, Iss. 1, pp. 5-115
Open Access | Times Cited: 376
Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation
Ildiko Lingvay, Priya Sumithran, Ricardo V. Cohen, et al.
The Lancet (2021) Vol. 399, Iss. 10322, pp. 394-405
Closed Access | Times Cited: 368
Ildiko Lingvay, Priya Sumithran, Ricardo V. Cohen, et al.
The Lancet (2021) Vol. 399, Iss. 10322, pp. 394-405
Closed Access | Times Cited: 368
2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
Sandeep R. Das, Brendan M. Everett, Kim K. Birtcher, et al.
Journal of the American College of Cardiology (2020) Vol. 76, Iss. 9, pp. 1117-1145
Open Access | Times Cited: 347
Sandeep R. Das, Brendan M. Everett, Kim K. Birtcher, et al.
Journal of the American College of Cardiology (2020) Vol. 76, Iss. 9, pp. 1117-1145
Open Access | Times Cited: 347
Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus
Thomas A. Zelniker, Marc P. Bonaca, Remo H.M. Furtado, et al.
Circulation (2020) Vol. 141, Iss. 15, pp. 1227-1234
Open Access | Times Cited: 343
Thomas A. Zelniker, Marc P. Bonaca, Remo H.M. Furtado, et al.
Circulation (2020) Vol. 141, Iss. 15, pp. 1227-1234
Open Access | Times Cited: 343
Emerging Targets in Type 2 Diabetes and Diabetic Complications
Sevgican Demir, Peter P. Nawroth, Stephan Herzig, et al.
Advanced Science (2021) Vol. 8, Iss. 18
Open Access | Times Cited: 318
Sevgican Demir, Peter P. Nawroth, Stephan Herzig, et al.
Advanced Science (2021) Vol. 8, Iss. 18
Open Access | Times Cited: 318
A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives
Josh Reed, Stephen C. Bain, Venkateswarlu Kanamarlapudi
Diabetes Metabolic Syndrome and Obesity (2021) Vol. Volume 14, pp. 3567-3602
Open Access | Times Cited: 290
Josh Reed, Stephen C. Bain, Venkateswarlu Kanamarlapudi
Diabetes Metabolic Syndrome and Obesity (2021) Vol. Volume 14, pp. 3567-3602
Open Access | Times Cited: 290
